Aveanna Healthcare Holdings, Inc.

Listed Company

AVAHCIK 0001832332NasdaqAcceleratedServices-Home Health Care ServicesDelawareFY ends Jan 1

Period

FY 2025

Revenue

$2.43B

Net Income

$225.03M

Total Assets

$2.01B

Equity

$194.46M

Shares Out

217.51M

Op. Cash Flow

$125.86M

Business

Aveanna Healthcare Holdings, Inc. operates a diversified home care platform delivering in-home clinical and non-clinical care to medically complex patients across the lifespan. It offers private duty nursing and pediatric therapy, adult home health and hospice, enteral nutrition and respiratory supplies, durable medical equipment, respite and personal care, and caregiver education and support. The company manages three business segments—Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). Aveanna distributes services nationally across multiple U.S. states via branch operations, hospital and referral partnerships, payer contracts (Medicaid, Medicare, MCOs, commercial insurers) and direct home delivery and logistics.

Summary from filing dated 2025-03-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	2,433	2,025	1,895	1,788	1,679
Cost of revenue, excluding depreciation and amortization	1,623	1,389	1,300	1,234	1,136
Branch and regional administrative expenses	374	353	361	357	297
Corporate expenses	163	125	113	138	130
Depreciation and amortization	11	11	14	21	21
Acquisition-related costs	4	1	466,000	99,000	13
Other operating expense	2	5	−6	4	−337,000
Operating income	256	140	8	−642	−36
Interest income	3	498,000	327,000	679,000	253,000
Interest expense	−140	−157	−153	−108	−69
Loss on debt extinguishment	−6	0	—	—	−14
Other (expense) income	−6	21	6	86	5
Income before income taxes	107	5	−139	−664	−114
Income tax benefit (expense)	118	−16	4	2	−3
Net income (loss)	225	−11	−135	−662	−117
Net income (loss) per share, basic	1.11	−0.06	−0.71	−3.57	−0.69
Weighted average shares of common stock outstanding, basic	204	193	190	186	170,625
Net income (loss) per share, diluted	1.05	−0.06	−0.71	−3.57	−0.69
Weighted average shares of common stock outstanding, diluted	215	193	190	186	170,625

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	193	84	44	19	30
Patient accounts receivable	313	265	237	221	219
Receivables under insured programs	3	12	9	4	6
Prepaid expenses	21	17	16	15	14
Other current assets	30	13	9	10	9
Total current assets	560	393	315	270	279
Property and equipment, net	17	17	21	23	31
Operating lease right of use assets	39	41	49	55	52
Goodwill	1,121	1,055	1,055	1,160	1,836
Intangible assets, net	93	90	94	96	103
Receivables under insured programs	29	22	21	23	26
Deferred income taxes	137	—	—	—	—
Other long-term assets	17	46	58	86	8
Total assets	2,012	1,663	1,613	1,712	2,334
Accounts payable and other accrued liabilities	32	36	30	45	53
Accrued payroll and employee benefits	108	88	67	44	55
Current portion of insurance reserves - insured programs	3	12	9	4	6
Current portion of insurance reserves	17	18	21	28	13
Securitization obligations	165	169	155	140	120
Current portion of long-term obligations	13	9	9	9	9
Current portion of operating lease liabilities	16	15	15	13	14
Other current liabilities	70	54	48	44	50
Total current liabilities	424	402	355	326	345
Long-term obligations, less current portion	1,287	1,272	1,276	1,281	1,227
Long-term insurance reserves - insured programs	29	22	21	23	26
Long-term insurance reserves	49	45	40	35	35
Operating lease liabilities, less current portion	27	32	40	46	45
Deferred income taxes	—	6	5	4	3
Other long-term liabilities	800,000	7	3	359,000	17
Total liabilities	1,817	1,785	1,740	1,716	1,696
Commitments and contingencies (Note 14)	—	—	—	—	—
Deferred restricted stock units	730,000	1	2	2	2
Preferred stock, $0.01 par value as of January 3, 2026 and December 28, 2024 5,000,000 shares authorized; none issued or outstanding	—	—	—	—	—
Common stock, $0.01 par value, 1,000,000,000 shares authorized; 210,996,359 and 193,225,177 issued and outstanding, respectively	2	2	2	2	2
Additional paid-in capital	1,349	1,257	1,240	1,229	1,209
Accumulated deficit	−1,157	−1,382	−1,371	−1,237	−575
Total stockholders' equity (deficit)	194	−124	−130	−6	636
Total liabilities, deferred restricted stock units, and stockholders' equity (deficit)	2,012	1,663	1,613	1,712	2,334

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income (loss)	225	−11	−135	−662	−117
Amortization of deferred debt issuance costs	6	5	5	8	9
Reduction in carrying amount of operating lease right of use assets	18	20	16	18	15
Non-cash share-based compensation	25	17	13	16	14
Loss on disposal or impairment of licenses, property and equipment, and software	2	3	3	4	110,000
Fair value adjustments on interest rate derivatives	30	15	28	−85	−14
Deferred income taxes	−143	1	1	−115,000	1
Patient accounts receivable	−30	−29	−15	−3	−9
Prepaid expenses	6	6	7	9	7
Other current and long-term assets	−27	−21	−17	−2	−4
Accounts payable and other accrued liabilities	−6	6	−14	−4	−12
Accrued payroll and employee benefits	16	21	23	−11	−14
Insurance reserves	2	2	−2	18	2
Operating lease liabilities	−19	−20	−15	−20	−16
Other current and long-term liabilities	6	4	9	−5	−9
Net cash provided by operating activities	126	33	23	−48	−11
Acquisitions of businesses, net of cash acquired	−15	0	—	−2	−667
Purchases of property and equipment, and software	−7	−6	−6	−12	−16
Net cash used in investing activities	−22	−6	−9	−25	−682
Payments for shares withheld to cover employee taxes on vesting of restricted stock	−6	0	—	—	—
Proceeds from exercise of options	212,000	0	—	—	970,000
Proceeds from employee stock purchase plan	6	3	945,000	4	2
Proceeds from securitization obligation	0	25	50	40	150
Repayment of securitization obligation	−4	−11	−35	−20	−30
Proceeds from issuance of term loans, net of debt issuance costs	1,318	0	—	60	1,325
Principal payments on term loans	−1,309	−9	−9	−9	−1,274
Principal payments on notes payable	−9	−7	−10	−10	−8
Principal payments on financing lease obligations	0	−267,000	−665,000	−799,000	−795,000
Payment of debt issuance costs	−4	−2	−1	−218,000	−15
Settlements with interest rate swap counterparties	13	15	16	−2	—
Net cash provided by financing activities	5	14	11	62	586
Net change in cash and cash equivalents	109	40	25	−11	−107
Cash paid for interest	143	153	138	103	59
U.S. Federal	24	—	—	—	—
California	3	—	—	—	—
Other State and Local	3	—	—	—	—
Foreign	0	—	—	—	—
Total Cash paid for income taxes, net of refunds received	31	6	1	2	5
Financed insurance premiums	9	8	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro